STOCKHOLM, Oct. 4, 2019 /PRNewswire/ -- RaySearch has
received a new regulatory clearance from the Chinese authorities
NMPA (previously CFDA) for the treatment planning system
RayStation®. With this clearance RaySearch can continue to supply
the innovative and machine agnostic RayStation to customers in
China.
RayStation is designed for multi-modality support of many
different treatment delivery machines and is therefore well suited
for the large and varied market in China, with many different types of treatment
machines installed.
With its large population, China puts stringent requirement on speed and
efficiency in the treatment process in order to offer advanced
radiotherapy treatments to as many patients as possible. This also
suits RayStation well, as it has a strong automation focus and can
easily be scaled to fit each customer's needs and requirements.
Johan Löf, founder and CEO of RaySearch, says: "We are pleased
to have received this NMPA clearance so that we can provide
RayStation to the radiotherapy market in China. RayStation, with its leading position
in efficiency and performance, fits the rapidly growing demands
from customers in China very
well".
About RaySearch
RaySearch is a medical technology company that develops
innovative software solutions to improve cancer care. The company
markets the RayStation treatment planning system and RayCare®*, the
next-generation oncology information system, worldwide. Over 2,600
clinics in more than 65 countries use RaySearch's software to
improve life and outcomes for patients. The company was founded in
2000 and the share has been listed on Nasdaq Stockholm since
2003.
About RayCare
RayCare is designed to support the complex logistical challenges
of modern oncology clinics. It represents the future of oncology
information system technology, supporting the vision of one
oncology workflow. Many cancer patients receive a combination of
treatment types, and RayCare is designed to reflect that. It will
efficiently coordinate activities in radiation therapy,
chemotherapy and surgery and will offer advanced features for
clinical resource optimization, workflow automation and adaptive
radiation therapy. RayCare is being developed with tomorrow's
requirements for advanced analytics and decision support in
mind.
About RayStation
RayStation is a flexible, innovative treatment planning system,
chosen by many of the leading cancer centers worldwide. It combines
unique features such as unmatched adaptive therapy capabilities,
multi-criteria optimization, market-leading algorithms for IMRT and
VMAT optimization with highly accurate dose engines for photon,
electron, proton* and carbon ion* therapy. RayStation supports a
wide range of treatment machines, providing one control center for
all treatment planning needs and ensuring centers get greater value
from existing equipment. RayStation also seamlessly integrates with
RayCare, the next-generation oncology information system. By
harmonizing the treatment planning, we enable better care for
cancer patients worldwide.
More information about RaySearch is available at
www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46(0)8-510-530-00
johan.lof@raysearchlabs.com
Peter Thysell, CFO, RaySearch
Laboratories AB (publ)
Telephone: +46(0)70-661-05-59
peter.thysell@raysearchlabs.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/raysearch-laboratories/r/raysearch-has-received-new-regulatory-clearance-for-raystation-in-china,c2925278
The following files are available for download:
https://mb.cision.com/Main/1102/2925278/1118400.pdf
|
Release
|
https://news.cision.com/raysearch-laboratories/i/linkedin-pressrelease-rsl,c2695340
|
LinkedIn PressRelease
RSL
|
View original
content:http://www.prnewswire.com/news-releases/raysearch-has-received-new-regulatory-clearance-for-raystation-in-china-300931172.html
SOURCE RaySearch Laboratories